Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios*, J. Remon, S. Novello, N. Blais, R. Califano, T. Cufer, A. M. Dingemans, S. V. Liu, N. Peled, N. A. Pennell, M. Reck, C. Rolfo, D. Tan, J. Vansteenkiste, H. West, B. Besse

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)1686-1688
Number of pages3
JournalAnnals of Oncology
Volume30
Issue number11
DOIs
Publication statusPublished - Nov 2019

Keywords

  • NIVOLUMAB
  • DOCETAXEL
  • 1ST-LINE

Cite this

Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A. M., Liu, S. V., Peled, N., Pennell, N. A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H., & Besse, B. (2019). Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. Annals of Oncology, 30(11), 1686-1688. https://doi.org/10.1093/annonc/mdz295